FDA Approves New Treatment for Advanced Pancreatic Cancer

A new drug for the treatment of advanced (metastatic) pancreatic cancer received FDA approval.
A new drug for the treatment of advanced (metastatic) pancreatic cancer received FDA approval.

A new drug for the treatment of advanced (metastatic) pancreatic cancer received US Food and Drug Administration (FDA) approval.

The new drug, irinotecan liposome injection (Onivyde), is indicated for use in combination with fluorouracil and leucovorin to treat patients with advanced pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

Liposomal irinotecan was granted Priority Review and orphan drug designations. Priority Review status is granted to drugs that would significantly improve treatment options for a serious condition.

Orphan drug designation provides incentives to assist and encourage the development of drugs to treat rare diseases.

The National Cancer Institute (NCI) estimates 48,960 new cases of pancreatic cancer will be diagnosed in the United States in 2015, and almost as many deaths caused by the disease (40,560).

Pancreatic cancer is difficult to diagnose early, and treatment options are limited, especially in cases of metastatic disease and when resection is not possible.

The new drug's effectiveness was demonstrated in a randomized, open label study of 417 patients with metastatic pancreatic adenocarcinoma whose cancer had grown after undergoing treatment with gemcitabine or gemcitabine-based therapy.

The study was designed to determine whether patients receiving 1 of 3 regimens lived longer: liposomal irinotecan plus fluorouracil/leucovorin, liposomal irinotecan alone, or only fluorouracil/leucovorin.

Patients receiving liposomal irinotecan lived an average of 6.1 months compared with 4.2 months for those receiving only fluorouracil/leucovorin. No survival improvement was seen with irinotecan liposome injection compared with only fluorouracil/leucovorin.

The most common side effects reported were diarrhea, fatigue, vomiting, nausea, decreased appetite, stomatitis, and fever. Lymphopenia and neutropenia were noted; in addition, death due to sepsis following neutropenia was reported. Labeling includes a boxed warning about severe neutropenia and diarrhea.

Marketed by Merrimack Pharmaceuticals Inc of Cambridge, Massachusetts, Onivyde is not indicated for use as a single agent for the treatment of patients with metastatic pancreatic cancer.

REFERENCE

1. US Food and Drug Administration. FDA approved new treatment for advanced pancreatic cancer [press release]. FDA US Food and Drug Administration Web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468654.htm. Accessed October 23, 2015.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs